Effects of pantoprazole as a HIF-1α inhibitor on human gastric adenocarcinoma sgc-7901 cells

Neoplasma

Volumn 59, Issue 2, 2012, Pages 142-149

  Shen, Y ^a   Wu, Y ^a   Chen, M ^a   Shen, W ^a   Huang, S ^a   Zhang, L ^a   Zou, X ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Gastric cancer; HIF 1a; Proton pump inhibitors

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; HIF1A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TUMOR VOLUME; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; TUMOR CELL CULTURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOCARCINOMA; ANIMALS; ANTI-ULCER AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, NUDE; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84863822889     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_019     Document Type: Article

References (37)

1. WANG GL, JIANG BH, RUE EA, SEMENZA GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514. http://dx.doi.org/10.1073/pnas.92.12.5510
2. WANG GL, SEMENZA GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270: 1230-1237. http://dx.doi.org/10.1074/jbc.270.3.1230
3. MARÍN-HERNÁNDEZ A, GALLARDO-PÉREZ JC, RALPH SJ, RODRÍGUEZ-ENRÍQUEZ S, MORENO-SÁNCHEZ R. HIF-1α modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009; 9: 1084-1101. http://dx.doi. org/10.2174/138955709788922610
4. POON E, HARRIS AL, ASHCROFT M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 2009; 11: e26. http://dx.doi.org/10.1017/S1462399409001173
5. VAUPEL P, MAYER A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-239. http://dx.doi.org/10.1007/s10555-007-9055-1
6. LIAO D, JOHNSON RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007;26: 281-290. http://dx.doi.org/10.1007/s10555-007-9066-y
7. MABJEESH NJ, ESCUIN D, LAVALLEE TM, PRIBLUDA VS, SWARTZ GM et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363-375. http://dx.doi.org/10.1016/S1535-6108(03)00077-1
8. BOU KHEIR T, FUTOMA-KAZMIERCZAK E, JACOBSEN A, KROGH A, BARDRAM L et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer 2011; 10: 29. http://dx.doi.org/10.1186/1476-4598-10-29
9. MIZOKAMI K, KAKEJI Y, ODA S, IRIE K, YONEMURA T et al. Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas. J Surg Oncol 2006; 94: 149-154. http://dx.doi.org/10.1002/jso.20568
10. SUMIYOSHI Y, KAKEJI Y, EGASHIRA A, MIZOKAMI K, ORITA H et al. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 2006; 12: 5112-5117. http://dx.doi.org/10.1158/1078-0432.CCR-05-2382
11. URANO N, FUJIWARA Y, DOKI Y, TSUJIE M, YAMAMOTO H et al. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer 2006; 9: 44-49. http://dx.doi.org/10.1007/s10120-005-0356-1
12. GRIFFITHS EA, PRITCHARD SA, VALENTINE HR, WHITCHELO N, BISHOP PW et al. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 2007; 96: 95-103. http://dx.doi. org/10.1038/sj.bjc.6603524
13. YEO EJ, CHUN YS, CHO YS, KIM J, LEE JC et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95: 516-525. http://dx.doi. org/10.1093/jnci/95.7.516
14. STOELTZING O, MCCARTY MF, WEY JS, FAN F, LIU W et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004;96: 946-956. http://dx.doi.org/10.1093/jnci/djh168
15. YEO M, KIM DK, KIM YB, OH TY, LEE JE et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 2004; 10: 8687-8696. http://dx.doi.org/10.1158/1078-0432.CCR-04-1065
16. RYAN HE, POLONI M, MCNULTY W, ELSON D, GASSMANN M et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000; 60: 4010-4015.
17. FANG J, ZHOU Q, LIU LZ, XIA C, HU X et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1α and VEGF expression. Carcinogenesis 2007; 28: 858-864. http://dx.doi.org/10.1093/carcin/bgl205
18. MIYAZAWA M, YASUDA M, FUJITA M, HIRABAYASHI K, HIRASAWA T et al. Granulosa cell tumor with activated mTOR-HIF-1α-VEGF pathway. J Obstet Gynaecol Res 2010; 36: 448-453. http://dx.doi.org/10.1111/j.1447-0756.2009.01127.x
19. CARMELIET P, DOR Y, HERBERT JM, FUKUMURA D, BRUSSELMANS K et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490. http://dx.doi.org/10.1038/28867
20. AN WG, KANEKAL M, SIMON MC, MALTEPE E, BLAGOSKLONNY MV et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 1998; 392: 405-408. http://dx.doi.org/10.1038/32925
21. CHEN M, ZOU X, LUO H, CAO J, ZHANG X et al. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol Int 2009; 33: 1008-1019. http://dx.doi.org/10.1016/j.cellbi.2009.05.004
22. BÖDVARSDÓTTIR TB, HOVE KD, GOTFREDSEN CF, PRIDAL L, VAAG A et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 2010; 53: 2220-2223. http://dx.doi.org/10.1007/s00125-010-1825-6
23. TAKAGI T, NAITO Y, OKADA H, ISHII T, MIZUSHIMA K et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. J Pharmacol Exp Ther 2009; 331: 255-264. http://dx.doi. org/10.1124/jpet.109.152702
24. SCHILLINGER W, TEUCHER N, SOSSALLA S, KETTLEWELL S, WERNER C et al. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation 2007; 116: 57-66. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.666008
25. MAJUMDER PK, FEBBO PG, BIKOFF R, BERGER R, XUE Q et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601. http://dx.doi.org/10.1038/nm1052
26. WAN X, SHEN N, MENDOZA A, KHANNA C HELMAN LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF Signaling. Neoplasia 2006; 8: 394-401. http://dx.doi.org/10.1593/neo.05820
27. PENG XH, KARNA P, CAO Z, JIANG BH, ZHOU M et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006; 281: 25903-25914. http://dx.doi.org/10.1074/jbc. M603414200
28. MAYERHOFER M, VALENT P, SPERR WR, GRIFFIN JD SILLABER C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767-3775. http://dx.doi. org/10.1182/blood-2002-01-0109
29. KOUKOURAKIS MI, SIMOPOULOS C, POLYCHRONIDIS A, PERENTE S, BOTAITIS S et al. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIF1α/VEGF pre-treatment status? Anticancer Res 2003; 23: 1673-1680.
30. HARRIS AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47. http://dx.doi.org/10.1038/nrc704
31. MAXWELL PH, WIESENER MS, CHANG GW, CLIFFORD SC, VAUX EC et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275. http://dx.doi. org/10.1038/2045
32. JAAKKOLA P, MOLE DR, TIAN YM, WILSON MI, GIELBERT J et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472. http://dx.doi.org/10.1126/science.1059796
33. MEKHAIL K, GUNARATNAM L, BONICALZI ME LEE S. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat. Cell Biol. 2004; 6: 642-647. http://dx.doi. org/10.1038/ncb1144
34. LUCIANI F, SPADA M, MILITO AD, MOLINARI A, RIVOLTINI L et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96: 1702-1713. http://dx.doi.org/10.1093/jnci/djh305
35. WON MS, IM N, PARK S, BOOVANAHALLI SK, JIN Y et al. A novel benzimidazole analogue inhibits the hypoxiainducible factor (HIF)-1 pathway. Biochem Biophys Res Commun 2009; 385: 16-21. http://dx.doi.org/10.1016/j.bbrc.2009.05.022
36. HÄNZE J, EUL BG, SAVAI R, KRICK S, GOYAL P et al. RNA interference for HIF-1α inhibits its downstream signalling and affects cellular proliferation. Biochem Biophys Res Commun 2003; 312: 571-577. http://dx.doi.org/10.1016/j.bbrc.2003.10.153
37. BRUEGGE K, JELKMANN W METZEN E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-α hydroxylases. Curr Med Chem 2007; 14: 1853-1862.